Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309477035> ?p ?o ?g. }
- W4309477035 endingPage "1163" @default.
- W4309477035 startingPage "1141" @default.
- W4309477035 abstract "To update the CCAFU recommendations for the management of muscle invasive bladder carcinoma (MIBC).A systematic review (Medline) of the literature from 2020 to 2022 was performed taking account of the diagnosis, treatment options and surveillance of NMIBC and MIBC, while evaluating the references with their levels of evidence.MIBC is diagnosed after the most complete tumour resection possible. MIBC grading is based on CTU along with chest CT. Multiparametric pelvic MRI could be an alternative. Cystectomy with extensive lymphadenectomy is the gold standard treatment for non-metastatic MIBC. It should be preceded by platinum-based neoadjuvant chemotherapy in patients in good general health with satisfactory renal function. Enterocystoplasty is proposed in men and women in the absence of contraindications and when the urethral resection is negative on extemporaneous examination. Otherwise, transileal cutaneous ureterostomy is the recommended method of urinary diversion. Inclusion of all patients in an ERAS (Enhanced Recovery After Surgery) protocol is recommended. For metastatic MIBC, first line treatment with platinum-based chemotherapy (GC or MVAC) is recommended, if general health (PS>1) and renal function (clearance>60mL/min) so allow (only 50% of the cases). Pembrolizumab immunotherapy has demonstrated an overall survival benefit in second-line treatment.Updating the ccAFU recommendations should contribute to improving patient management, as well as the diagnosis and decision-making concerning MIBC treatment." @default.
- W4309477035 created "2022-11-28" @default.
- W4309477035 creator A5016602967 @default.
- W4309477035 creator A5019609561 @default.
- W4309477035 creator A5027991868 @default.
- W4309477035 creator A5033054923 @default.
- W4309477035 creator A5036150713 @default.
- W4309477035 creator A5038866794 @default.
- W4309477035 creator A5041684870 @default.
- W4309477035 creator A5042627197 @default.
- W4309477035 creator A5046873085 @default.
- W4309477035 creator A5064914239 @default.
- W4309477035 creator A5084326149 @default.
- W4309477035 creator A5090538658 @default.
- W4309477035 date "2022-11-01" @default.
- W4309477035 modified "2023-10-16" @default.
- W4309477035 title "French AFU Cancer Committee Guidelines – Update 2022–2024: Muscle-Invasive Bladder Cancer (MIBC)" @default.
- W4309477035 cites W1538193234 @default.
- W4309477035 cites W1556453357 @default.
- W4309477035 cites W1845540772 @default.
- W4309477035 cites W1857682357 @default.
- W4309477035 cites W1902718972 @default.
- W4309477035 cites W1963508876 @default.
- W4309477035 cites W1964037817 @default.
- W4309477035 cites W1973345553 @default.
- W4309477035 cites W1974478801 @default.
- W4309477035 cites W1975848770 @default.
- W4309477035 cites W1985950314 @default.
- W4309477035 cites W1988672352 @default.
- W4309477035 cites W1999472020 @default.
- W4309477035 cites W2001420809 @default.
- W4309477035 cites W2006283915 @default.
- W4309477035 cites W2019106289 @default.
- W4309477035 cites W2026291233 @default.
- W4309477035 cites W2045868842 @default.
- W4309477035 cites W2053622035 @default.
- W4309477035 cites W2067512845 @default.
- W4309477035 cites W2069853214 @default.
- W4309477035 cites W2076445381 @default.
- W4309477035 cites W2088357516 @default.
- W4309477035 cites W2103257412 @default.
- W4309477035 cites W2120955645 @default.
- W4309477035 cites W2121637004 @default.
- W4309477035 cites W2123910478 @default.
- W4309477035 cites W2123981884 @default.
- W4309477035 cites W2125675894 @default.
- W4309477035 cites W2134389360 @default.
- W4309477035 cites W2135143649 @default.
- W4309477035 cites W2152762320 @default.
- W4309477035 cites W2154214827 @default.
- W4309477035 cites W2157993620 @default.
- W4309477035 cites W2158441801 @default.
- W4309477035 cites W2164361265 @default.
- W4309477035 cites W2167333057 @default.
- W4309477035 cites W2169378506 @default.
- W4309477035 cites W2230855427 @default.
- W4309477035 cites W2246613296 @default.
- W4309477035 cites W2270048453 @default.
- W4309477035 cites W2332342311 @default.
- W4309477035 cites W2402719057 @default.
- W4309477035 cites W2427422371 @default.
- W4309477035 cites W2528981680 @default.
- W4309477035 cites W2571353830 @default.
- W4309477035 cites W2588916311 @default.
- W4309477035 cites W2589348657 @default.
- W4309477035 cites W2606173101 @default.
- W4309477035 cites W2735568791 @default.
- W4309477035 cites W2751602009 @default.
- W4309477035 cites W2766718867 @default.
- W4309477035 cites W2767805252 @default.
- W4309477035 cites W2769902165 @default.
- W4309477035 cites W2770869232 @default.
- W4309477035 cites W2792297276 @default.
- W4309477035 cites W2796679514 @default.
- W4309477035 cites W2800613296 @default.
- W4309477035 cites W2805863339 @default.
- W4309477035 cites W2809685212 @default.
- W4309477035 cites W2883475115 @default.
- W4309477035 cites W2893208123 @default.
- W4309477035 cites W2900683197 @default.
- W4309477035 cites W2904174949 @default.
- W4309477035 cites W2909260920 @default.
- W4309477035 cites W2914472350 @default.
- W4309477035 cites W2914908474 @default.
- W4309477035 cites W2952662001 @default.
- W4309477035 cites W2964014383 @default.
- W4309477035 cites W2969232182 @default.
- W4309477035 cites W2975105339 @default.
- W4309477035 cites W2975300000 @default.
- W4309477035 cites W2977747933 @default.
- W4309477035 cites W2981454286 @default.
- W4309477035 cites W2996420889 @default.
- W4309477035 cites W2996758620 @default.
- W4309477035 cites W3007380031 @default.
- W4309477035 cites W3011470625 @default.
- W4309477035 cites W3012438829 @default.
- W4309477035 cites W3012670892 @default.
- W4309477035 cites W3014906130 @default.